Last reviewed · How we verify
NCT05916014
AI-assisted White Light Endoscopy to Identify the Kimura-Takemoto Classification of Atrophic Gastritis
trial testing Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists in Atrophic Gastritis in 1,500 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Shandong University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 1 June 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists
Conditions studied
- Atrophic Gastritis — all drugs for Atrophic Gastritis →
- Artificial Intelligence — all drugs for Artificial Intelligence →
- Endoscopy — all drugs for Endoscopy →
Sponsor
Shandong University
Who can join
Adults 18 to 80, any sex, with Atrophic Gastritis or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Grading endoscopic atrophy according to the Kimura-Takemoto classification can assess the risk of gastric neoplasia development. However, the false negative rate of chronic atrophic gastritis is high due to the varying diagnostic standardization and diagnostic experience and levels of endoscopists. Therefore, this study aims to develop an AI model to identify the Kimura-Takemoto classification.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Role of Artificial Intelligence in the Management of Gastric Cancer.
Liatsou E, Driva TS, Vergadis C, Sakellariou S, et al · · 2025 · PMID 41462951 · DOI 10.3390/biomedicines13122939
Verify or expand the search:
- PubMed search for NCT05916014
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atrophic Gastritis
Currently open trials in the same condition.
- NCT06203327 — Atrophic Gastritis Predicts the Risk of Gastric Cancer · recruiting
- NCT07388459 — Natural History, Evolution, and Clinical Features of Autoimmune Atrophic Gastritis · recruiting
- NCT04840056 — Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis · recruiting
- NCT04613570 — SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up · NA · recruiting
- NCT05053945 — Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study · recruiting
Other Shandong University trials
Trials by the same sponsor.
- NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
- NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
- NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
- NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
- NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05916014 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong University
- Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05916014.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing